3 Stocks Driving The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 203 points (-1.1%) at 18,029 as of Tuesday, May 26, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 617 issues advancing vs. 2,410 declining with 142 unchanged.

The Health Care sector currently sits down 0.8% versus the S&P 500, which is down 1.0%. On the negative front, top decliners within the sector include GlaxoSmithKline ( GSK), down 2.7%, Sanofi ( SNY), down 2.6%, AstraZeneca ( AZN), down 2.6%, Alexion Pharmaceuticals ( ALXN), down 2.5% and Amgen ( AMGN), down 2.4%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. bluebird bio ( BLUE) is one of the companies pushing the Health Care sector higher today. As of noon trading, bluebird bio is up $9.58 (5.4%) to $187.96 on heavy volume. Thus far, 710,420 shares of bluebird bio exchanged hands as compared to its average daily volume of 762,700 shares. The stock has ranged in price between $177.06-$189.06 after having opened the day at $178.48 as compared to the previous trading day's close of $178.38.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Bluebird bio has a market cap of $5.9 billion and is part of the drugs industry. Shares are up 94.5% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates bluebird bio as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full bluebird bio Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Mylan ( MYL) is up $1.08 (1.6%) to $70.74 on light volume. Thus far, 2.8 million shares of Mylan exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $69.49-$71.05 after having opened the day at $69.50 as compared to the previous trading day's close of $69.66.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $34.1 billion and is part of the drugs industry. Shares are up 23.6% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Mylan Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, AbbVie ( ABBV) is up $1.27 (1.9%) to $66.75 on heavy volume. Thus far, 9.5 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.5 million shares. The stock has ranged in price between $65.66-$66.92 after having opened the day at $65.72 as compared to the previous trading day's close of $65.48.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $104.3 billion and is part of the drugs industry. Shares are up 0.1% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full AbbVie Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

If you liked this article you might like

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017